nach oben

Endocrine Pathology

Erschienen in:

01.03.2014

The Adrenal Medulla and Extra-adrenal Paraganglia: Then and Now

verfasst von: Arthur S. Tischler, Karel Pacak, Graeme Eisenhofer

Erschienen in: Endocrine Pathology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The past 25 years have witnessed revolutionary changes in the care of patients with pheochromocytomas and extra-adrenal paragangliomas. Germline mutations of at least 13 genes are now associated with tumor development, a greater degree of hereditary susceptibility than for any other human neoplasm. Somatic mutations, either of the same genes or of several additional ones with closely related functions, are also increasingly recognized. Clinicians are now aware of the genetic implications of a pheochromocytoma or paraganglioma. All patients are therefore offered genetic testing and receive lifelong surveillance. Almost all of the mutated genes have well-described correlations with clinical and biochemical phenotypes. Tumors arising in patients with mutations of the SDHB gene have at least a 30 % chance of metastasizing and typically produce norepinephrine and/or dopamine. Assay of plasma-free metanephrines serves as a highly sensitive and specific biochemical screen for the presence of catecholamine-producing tumors, and the dopamine metabolite methoxytyramine serves as a useful marker for detecting minimally functional tumors or their metastases. New functional imaging techniques provide highly sensitive tumor localization. In addition to differential diagnosis, pathologists play new roles in helping to identify hereditary disease and guiding the sequence of genetic testing.

Gimenez-Roqueplo AP, Dahia PL, Robledo M: An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 44:328–33, 2012PubMedCrossRef

Baysal BE, Ferrell RE, Willett-Brozick JE, et al.: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848–51, 2000PubMedCrossRef

Niemann S, Muller U: Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26:268–70, 2000PubMedCrossRef

Astuti D, Latif F, Dallol A, et al.: Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49–54, 2001PubMedCentralPubMedCrossRef

Neumann HP, Bausch B, McWhinney SR, et al.: Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–66., 2002PubMedCrossRef

Boedeker CC, Hensen EF, Neumann HP, et al.: Genetics of hereditary head and neck paragangliomas. Head Neck 2013

Pasini B, Stratakis CA: SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 266:19–42, 2009PubMedCrossRef

Malinoc A, Sullivan M, Wiech T, et al.: Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endocr Relat Cancer 19:283–90, 2012PubMedCrossRef

Xekouki P, Stratakis CA: Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer 19:C33–40, 2012PubMedCentralPubMedCrossRef

10.

Beckers A: Means, motive, and opportunity: SDH mutations are suspects in pituitary tumors. J Clin Endocrinol Metab 98:2274–6, 2013PubMedCrossRef

11.

Eisenhofer G, Tischler AS, de Krijger RR: Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol 23:4–14, 2012PubMedCrossRef

12.

Jimenez C, Rohren E, Habra MA, et al.: Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep 15:356–71, 2013PubMedCrossRef

13.

Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, et al.: Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 24:2382–91, 2010PubMedCrossRef

14.

Shankavaram U, Fliedner SM, Elkahloun AG, et al.: Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. Neoplasia 15:435–47, 2013PubMedCentralPubMed

15.

Dahia PL: The genetic landscape of pheochromocytomas and paragangliomas: somatic mutations take center stage. J Clin Endocrinol Metab 98:2679–81, 2013PubMedCrossRef

16.

Burnichon N, Buffet A, Parfait B, et al.: Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 21:5397–405, 2012PubMedCrossRef

17.

Toledo RA, Qin Y, Srikantan S, et al.: In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer 20:349–59, 2013PubMedCrossRef

18.

Pacak K, Jochmanova I, Prodanov T, et al.: New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol 31:1690–8, 2013PubMedCrossRef

19.

Crona J, Delgado Verdugo A, Maharjan R, et al.: Somatic Mutations in H-RAS in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing. J Clin Endocrinol Metab 2013

20.

Eisenhofer G, Goldstein DS, Kopin IJ, Crout JR: Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol 14:193–212, 2003PubMedCrossRef

21.

Manger WM: The protean manifestations of pheochromocytoma. Horm Metab Res 41:658–63, 2009PubMedCrossRef

22.

Timmers HJ, Pacak K, Huynh TT, et al.: Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. J Clin Endocrinol Metab 93:4826–32, 2008PubMedCentralPubMedCrossRef

23.

Balogova S, Talbot JN, Nataf V, et al.: ¹⁸F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging 40:943–66, 2013PubMedCentralPubMedCrossRef

24.

Hartung-Knemeyer V, Rosenbaum-Krumme S, Buchbender C, et al.: Malignant pheochromocytoma imaging with [124I]mIBG PET/MR. J Clin Endocrinol Metab 97:3833–4, 2012PubMedCrossRef

25.

Kabasakal L, Demirci E, Ocak M, et al.: Comparison of (6)(8)Ga-DOTATATE and (6)(8)Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 39:1271–7, 2012PubMedCrossRef

26.

Taieb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindie E: Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med 53:264–74, 2012PubMedCrossRef

27.

Timmers HJ, Taieb D, Pacak K: Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res 44:367–72, 2012PubMedCrossRef

28.

Ilias I, Pacak K: Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89:479–91, 2004PubMedCrossRef

29.

Taieb D, Timmers HJ, Hindie E, et al.: EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39:1977–95, 2012PubMedCrossRef

30.

Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, et al.: Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab 98:E162-73, 2013PubMedCrossRef

31.

Sharma P, Thakar A, Suman KCS, et al.: 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. J Nucl Med 54:841–7, 2013PubMedCrossRef

32.

Mayerhoefer ME, Ba-Ssalamah A, Weber M, et al.: Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. Eur Radiol 23:1978–85, 2013PubMedCrossRef

33.

Waguespack SG, Rich T, Grubbs E, et al.: A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 95:2023–37, 2010PubMedCrossRef

34.

Sovinz P, Urban C, Uhrig S, et al.: Pheochromocytoma in a 2.75-year-old-girl with a germline von Hippel–Lindau mutation Q164R. Am J Med Genet A 152A:1752–5, 2010PubMedCrossRef

35.

Benhammou JN, Boris RS, Pacak K, Pinto PA, Linehan WM, Bratslavsky G: Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel–Lindau syndrome after at least 5 years of followup. J Urol 184:1855–9, 2010PubMedCentralPubMedCrossRef

36.

Manny TB, Pompeo AS, Hemal AK: Robotic partial adrenalectomy using indocyanine green dye with near-infrared imaging: the initial clinical experience. Urology 82:738–42, 2013PubMedCrossRef

37.

Ayala-Ramirez M, Chougnet CN, Habra MA, et al.: Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 97:4040–50, 2012PubMedCentralPubMedCrossRef

38.

Chae YC, Angelin A, Lisanti S, et al.: Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun 4:2139, 2013PubMedCentralPubMedCrossRef

39.

Nolting S, Garcia E, Alusi G, et al.: Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J Mol Endocrinol 49:79–96, 2012PubMedCrossRef

40.

Welander J, Garvin S, Bohnmark R, et al.: Germline SDHA mutation detected by next-generation sequencing in a young index patient with large paraganglioma. J Clin Endocrinol Metab 98:E1379–80, 2013PubMedCrossRef

41.

Tischler AS: Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med 132:1272–84, 2008PubMed

42.

DeLellis RA, Lloyd RV, Heitz PU, Eng C: Tumours of Endocrine Organs. In World Health Organization Classification of Tumors. IARC Press, Lyon, 2004

43.

Linnoila RI, Keiser HR, Steinberg SM, Lack EE: Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21:1168–80, 1990PubMedCrossRef

44.

Thompson LD: Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26:551–66, 2002PubMedCrossRef

45.

Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y: Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16:23–32, 2005PubMedCrossRef

46.

Strong VE, Kennedy T, Al-Ahmadie H, et al.: Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143:759–68, 2008PubMedCrossRef

47.

Wu D, Tischler AS, Lloyd RV, et al.: Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol 33:599–608, 2009PubMedCrossRef

48.

Dahia PL, Ross KN, Wright ME, et al.: A HIF1alpha Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genet 1:e8, 2005PubMedCentralCrossRef

49.

van Nederveen FH, Gaal J, Favier J, et al.: An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10:764–71, 2009PubMedCrossRef

50.

Korpershoek E, Favier J, Gaal J, et al.: SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 96:E1472–6, 2011PubMedCrossRef

51.

Gill AJ: Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology 44:285–92, 2012PubMedCrossRef

52.

Erlic Z, Neumann HP: Diagnosing patients with hereditary paraganglial tumours. Lancet Oncol 10:741, 2009PubMedCrossRef

53.

Dahia PL, Ross KN, Wright ME, et al.: A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1:72–80, 2005PubMedCrossRef

54.

Dahia PL: Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas. Ann N Y Acad Sci 1073:208–20, 2006PubMedCrossRef

55.

Mete O, Tischler AS, R dK, et al.: Protocol for the Examination of Specimens from Patients with Pheochromocytomas and Extra-adrenal Paragangliomas. Arch Pathol Lab Med 2013

56.

Tudorancea A, Francois P, Trouillas J, et al.: Von Hippel–Lindau disease and aggressive GH-PRL pituitary adenoma in a young boy. Ann Endocrinol (Paris) 73:37–42, 2012CrossRef

57.

Kurozumi K, Tabuchi A, Ono Y, et al.: [Pituitary adenoma associated with neurofibromatosis type 1: case report]. No Shinkei Geka 30:741–5, 2002PubMed

58.

Dwight T, Mann K, Benn DE, et al.: Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab 98:E1103-8, 2013PubMedCrossRef

59.

Stratakis CA, Carney JA: The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney–Stratakis syndrome): molecular genetics and clinical implications. J Intern Med 266:43–52, 2009PubMedCentralPubMedCrossRef

60.

Bayley JP, Kunst HP, Cascon A, et al.: SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 11:366–72, 2010PubMedCrossRef

61.

Burnichon N, Briere JJ, Libe R, et al.: SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19:3011–20, 2010PubMedCentralPubMedCrossRef

62.

Qin Y, Yao L, King EE, et al.: Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 42:229–33, 2010PubMedCentralPubMedCrossRef

63.

Burnichon N, Cascon A, Schiavi F, et al.: MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18:2828–37, 2012PubMedCrossRef

64.

Astuti D, Ricketts CJ, Chowdhury R, et al.: Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer 18:73–83, 2011PubMedCentralPubMedCrossRef

65.

Lorenzo FR, Yang C, Ng Tang Fui M, et al.: A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) 91:507–12, 2013CrossRef

66.

Zhuang Z, Yang C, Lorenzo F, et al.: Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 367:922–30, 2012PubMedCentralPubMedCrossRef

67.

Schlisio S, Kenchappa RS, Vredeveld LC, et al.: The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 22:884–93, 2008PubMedCentralPubMedCrossRef

68.

Maher ER: HIF2 and endocrine neoplasia: an evolving story. Endocr Relat Cancer 20:C5–7, 2013PubMedCrossRef

Titel: The Adrenal Medulla and Extra-adrenal Paraganglia: Then and Now
verfasst von: Arthur S. Tischler
Karel Pacak
Graeme Eisenhofer
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Endocrine Pathology / Ausgabe 1/2014
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI: https://doi.org/10.1007/s12022-013-9286-3

Springer Medizin

The Adrenal Medulla and Extra-adrenal Paraganglia: Then and Now

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

A History of Pituitary Pathology

Neuroendocrine Tumors of the Pancreas: Current Concepts and Controversies

Editorial: The Birth of Endocrine Pathology

Understanding the Genetic Basis of Parathyroid Carcinoma

Pancreatic Pathology in Type 1 Diabetes Mellitus

Follicular-Patterned Afflictions of the Thyroid Gland: Reappraisal of the Most Discussed Entity in Endocrine Pathology

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie